Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

NCT07075471 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Study Locations (1)

North Carolina

  • Synexus Clinical Research, US INC — Wilmington

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-09-03
Est. Completion 2027-09

Sponsor

Deciphera Pharmaceuticals

42 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07075471

The ClinicalTrials.gov registry entry for NCT07075471 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Tenosynovial Giant Cell Tumor appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07075471 reports 1 study location spanning 1 distinct geographic area — top geographies include North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07075471 about?

NCT07075471 is a clinical study titled "Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib". The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the pa...

What is the current status of trial NCT07075471?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-09-03. Estimated completion is 2027-09.

What conditions does trial NCT07075471 study?

This clinical trial studies the following conditions: Tenosynovial Giant Cell Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT07075471?

This trial is sponsored by Deciphera Pharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07075471 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial